Connor, Clark & Lunn Investment Management (CC&L)’s Adaptive Biotechnologies ADPT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.9M	Buy	785,903 +136,276	+21%	+$2.09M	0.03%	407
2026 Q1	$9.02M	Buy	649,627 +58,303	+10%	+$929K	0.02%	498
2025 Q4	$9.6M	Buy	591,324 +535,380	+957%	+$8.74M	0.03%	472
2025 Q3	$837K	Buy	+55,944	New	+$682K	﹤0.01%	1115
2023 Q1	–	Sell	-89,119	Closed	-$681K	–	1221
2022 Q4	$681K	Sell	89,119 -179,896	-67%	-$1.4M	﹤0.01%	803
2022 Q3	$1.92M	Buy	269,015 +134,810	+100%	+$1.27M	0.01%	504
2022 Q2	$1.09M	Buy	134,205 +112,987	+533%	+$993K	0.01%	604
2022 Q1	$295K	Buy	21,218 +3,208	+18%	+$50.4K	﹤0.01%	878
2021 Q4	$505K	Sell	18,010 -5,564	-24%	-$171K	﹤0.01%	796
2021 Q3	$801K	Buy	+23,574	New	+$853K	﹤0.01%	681

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ADPT Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Adaptive Biotechnologies (ADPT) stake by 21% in Q2 2026, buying an estimated $2.09M and bringing the position to 785,903 shares worth $16.9M. The position accounts for 0.03% of the portfolio, ranked #407.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ADPT in Q3 2021 and has held it in 10 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 785,903 shares of Adaptive Biotechnologies worth $16.9M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 136,276 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.09M.
Adaptive Biotechnologies made up 0.03% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #407 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Adaptive Biotechnologies in Q3 2021 and has held it in 10 quarters since.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.